Publication | Closed Access
Effect of Palivizumab Prophylaxis on Subsequent Recurrent Wheezing in Preterm Infants
143
Citations
11
References
2013
Year
Palivizumab prophylaxis administered to preterm infants 33 to 35 weeks' gestational age is associated with a significantly lower incidence of recurrent wheezing during the first 3 years of life.
| Year | Citations | |
|---|---|---|
Page 1
Page 1